References
- Hattotuwa KL, Gizycki MJ, Ansari TW, Jeffrey PK, Barnes NC. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease. Am.Respir. Grit. Cam Med 165, 1592–1596 (2002).
- GOLD: Global Strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease NHLBI/ WHO workshop report — Executive Summary, 1998.
- Statistics: World Health Report 2002. www.who.int/whr/2000/en/statistics.htm
- Saetta M, Di Stefano A, Turato G et al CD+8 T-lymphocytes in the peripheral airways of smokers with chronic pulmonary disease. Am. Respir. Grit. Care Med. 157, 822–826 (1998).
- Majo J, Ghezzo H, Cosio MG. Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur. Respir. 17, 946–953 (2001).
- Callahan CM, Dittus RS, Katz BR Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease. A meta-analysis. Ann. Intern. Med 114, 216–223 (1991).
- Pauwels RA, Lofdahl CG, Laitinen LA et al Long-term effect of inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N. Eng. Med 340, 1948–1953 (1999).
- Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised double-blind placebo-controlled study of fluticasone propionate in patients with moderate to severe COPD. BE Med. 320, 1297–1303 (2000).
- Spencer S, Calverley PMA, Burge PS, Jones PW Health status deterioration in patients with chronic obstructive pulmonary disease. AIR I Respit: Grit. Care Med. 163, 122–128 (2001).
- BTS Guidelines for the management of chronic obstructive pulmonary disease. Thorax 52, S1—S28 (1997).
- Verhoeven GT, Garrelds IM, Hoogsteden HC, ZijIstra FJ. Effects of fluticasone propionate inhalation on levels of arachidonic acid metabolites in patients with chronic obstructive pulmonary disease. Mediators Inflamm. 10, 21–26 (2001).
- Balbi B, Majori M, Bertacco S eta]. Inhaled steroids in stable COPD patients: do they have effects on cells and molecular mediators of airway inflammation? Chest 117, 1633–1637 (2000).
- Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre, randomised, placebo-controlled trial of inhaled fluticasone propionate in subjects with chronic obstructive pulmonary disease: International COPD study group. Lancet 351, 773–780 (1998).
- Verhoeven GT, Hegmans JP, Mulder PG, Bogaard JM, Hoogsteden HC, Prins JB. Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness. Thomx57, 694–700 (2002).
- Turato G, Zuin R, Miniati M eta]. Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema. Am. Respir. Grit. Cam Med. 166, 105–110 (2002).
- Jarad NA, Wedzicha JA, Burge PS, Calverley PMA for the ISOLDE study group. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. Rasp Med 93, 161–166 (1999).